Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 647-654

  Amini Bavil Olyaee, Samad ^a   Herbers, Ulf ^a   Mohebbi, Seyed Reza ^b,c   Sabahi, Farzaneh ^c   Zali, Mohammad Reza ^b   Luedde, Tom ^a   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Adefovir; Drug resistance; Hepatitis B virus; Lamivudine; Polymorphism

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; VIRUS PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE LOCUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IRAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; STRUCTURAL GENE; VIRION; VIRUS GENE; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BASE SEQUENCE; CHILD; COHORT STUDIES; DNA PRIMERS; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOME, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IRAN; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POINT MUTATION; VIRUS REPLICATION; YOUNG ADULT;

EID: 69949156498     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.04.022     Document Type: Article

References (28)

1. Tacke F., Manns M.P., and Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance - implications for novel antiviral strategies. Curr Med Chem 11 (2004) 2667-2777
2. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-265
3. Bartholomeusz A., and Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 26 (2006) 162-170
4. Bartholomeusz A., Locarnini S.A., Ayres A., Thompson G., Sozzi V., Angus P., et al. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 40 (2004) 246
5. Bartholomeusz A., Locarnini S., Ayres A., Thompson G., Bowden S., Sozzi V., et al. Mechanistic basis for hepatitis B virus resistance to acyclid nucleoside phosphonate analogues, adefovir and tenofovir. Hepatology 42 (2005) 594
6. Ghany M., and Liang T.J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132 (2007) 1574-1585
7. Osiowy C., Villeneuve J.P., Heathcote E.J., Giles E., and Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 44 (2006) 1994-1997
8. Ciancio A., Smedile A., Rizzetto M., Lagget M., Gerin J., and Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 39 (2004) 64-73
9. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
10. Mohebbi S.R., Amini-Bavil-Olyaee S., Zali N., Noorinayer B., Derakhshan F., Chiani M., et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect 14 (2008) 858-866
11. Tacke F., Amini-Bavil-Olyaee S., Heim A., Luedde T., Manns M.P., and Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. J Clin Virol 38 (2007) 353-357
12. Tacke F., Liedtke C., Bocklage S., Manns M.P., and Trautwein C. CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut 54 (2005) 1309-1317
13. Tacke F., Gehrke C., Luedde T., Heim A., Manns M.P., and Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 78 (2004) 8524-8535
14. Henke-Gendo C., Amini-Bavil-Olyaee S., Challapalli D., Trautwein C., Deppe H., Schulz T.F., et al. Symptomatic hepatitis B reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 198 (2008) 1620-1624
15. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99 (2002) 15655-15660
16. Amini-Bavil-Olyaee S., Herbers U., Sheldon J., Luedde T., Trautwein C., and Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 49 (2009) 1158-1165
17. Amini-Bavil-Olyaee S., Sheldon J., Lutz T., Trautwein C., and Tacke F. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS 23 (2009) 268-272
18. Borroto-Esoda K., Miller M.D., and Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 47 (2007) 492-498
19. Moriconi F., Colombatto P., Coco B., Ciccorossi P., Oliveri F., Flichman D., et al. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother 60 (2007) 341-349
20. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
21. Gallego A., Sheldon J., Garcia-Samaniego J., Margall N., Romero M., Hornillos P., et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 15 (2008) 392-398
22. Angus P., Vaughan R., Xiong S., Yang H., Delaney W.E., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
23. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
24. Ono-Nita S.K., Kato N., Shiratori Y., Masaki T., Lan K.H., Carrilho F.J., et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29 (1999) 939-945
25. Locarnini S., and Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44 (2006) 422-431
26. Qi X., Xiong S., Yang H., Miller M., and Delaney W.E. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antiviral Ther 12 (2007) 355-362
27. Lada O., Benhamou Y., Cahour A., Katlama C., Poynard T., and Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antiviral Ther 9 (2004) 353-363
28. Yang H., Qi X., Sabogal A., Miller M., Xiong S., and Delaney W.E. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiviral Ther 10 (2005) 625-633